Literature DB >> 1979411

Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions.

L Mimms, D Vallari, L Ducharme, P Holland, I K Kuramoto, J Zeldis.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 1979411     DOI： 10.1016/0140-6736(90)93377-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

2.  Correlation of serum antibody titers against hepatitis C virus core protein with clinical features by western blot (immunoblot) analysis using a recombinant vaccinia virus expression system.

Authors:  A Nishizono; M Hiraga; K Mifune; H Terao; T Fujioka; M Nasu; T Goto; J Misumi; M Moriyama; Y Arakawa
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

3.  Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs.

Authors:  J P Allain; S H Dailey; Y Laurian; D S Vallari; A Rafowicz; S M Desai; S G Devare
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

4.  Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; M Sawada
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

5.  Evaluation of three hepatitis C virus-related antibodies C100, KCL-163, JCC. Tests for screening blood donors.

Authors:  S Fujiyama; S Kawano; S Sato; T Sato; T Kawahara; K Mizuno; Y Kusumoto; M Esumi; T Shikata
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

6.  Immunodominant regions within the hepatitis C virus core and putative matrix proteins.

Authors:  M Sällberg; U Rudén; B Wahren; L O Magnius
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

7.  High prevalence of hepatitis B and C viral markers in Japanese patients with hepatocellular carcinoma.

Authors:  N Tanaka; T Chiba; Y Matsuzaki; T Osuga; T Aikawa; K Mitamura
Journal:  Gastroenterol Jpn       Date:  1993-08

8.  Serological markers of posttransfusion hepatitis C viral infection.

Authors:  D S Vallari; B W Jett; H J Alter; L T Mimms; R Holzman; J W Shih
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

9.  Clinical evaluation of three anti-HCV ELISAs in patients with various liver diseases.

Authors:  S Kawano; S Fujiyama; S Sato; M Tanaka; M Goto; Y Taura; T Sato; T Kawahara; K Mizuno; S Nonaka
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

10.  Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection.

Authors:  L T Mimms; J W Mosley; F B Hollinger; R D Aach; C E Stevens; M Cunningham; D V Vallari; L H Barbosa; G J Nemo
Journal:  BMJ       Date:  1993-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.